Studies why some people have lasting lung problems after COVID-19
Observes adults with lasting shortness of breath after severe COVID-19 infection.
Plain-language title generated from the registry record
Registry title: A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae
Key facts
- Where
- Rochester, United StatesSee the site
Where in United States
- Mayo Clinic MinnesotaRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT06006884
- Record updated
- 7 May 2026
- Original description
The purpose of this study is to understand why some people experience long term effects, such as shortness of breath and fatigue, after a severe COVID-19 infectionRead full original descriptionShow less
Uncover Mechanisms Underlying the Development of Chronic Lung Sequelae Post COVID-19
The purpose of this study is to understand why some people experience long term effects, such as shortness of breath and fatigue, after a severe COVID-19 infection
Inclusion: For the Sequelae Group; Age ≥18 years at screening, PCR confirmed COVID19 illness (+PCR defines day 0 of illness), hospitalization for COVID-19, absence of pre-existing history of interstitial lung disease, or significant other lung disease; Severity of illness will be categorized as moderate disease (supplemental oxygen need 1-8L at any time during hospitalization), severe disease (need for high flow oxygen delivery ≥8L at any time during hospitalization) and critical illness (need for ICU admission or mechanical ventilation); Control Recovery Group; Age ≥18 years at screening; PCR confirmed COVID-19 cases who had nonsymptomatic or mild acute infection that do not require hospitalization 7,48,49; Absence of pre-existing history of interstitial lung disease, or significant other lung disease, absence of any ongoing respiratory and systemic symptoms.
Exclusion: Immunocompromised host status due to ongoing therapy with methotrexate, CellCept, azathioprine, rituximab, cyclophosphamide or other biologic agents; Inability to provide informed consent, evidence of pre-existing interstitial lung disease or chronic lung disease; History of chemotherapy or radiation therapy in the last two years; and pregnancy; Active cigarette smoking, vaping or other inhalation use; > 20 pack year smoking history.